ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M

* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20199129-ars-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-accelerating] (NASDAQ:SPRY [https://seekingalpha.com/symbol/SPRY]): Q2 GAAP EPS of -$0.46 beats by $0.01.
* Revenue of $15.72M beats by $1.94M.
* Total revenue for the second quarter of 2025 was $15.7 million, which was comprised of $12.8 million in net product revenue from _neffy_ sales in the U.S., $2.6 million in milestone revenue from ALK-Abelló A/S (ALK [https://seekingalpha.com/symbol/ALK]) related to the launch of EUR_neffy_® in Germany, and $0.3 million in supply revenue from partners. The cash milestone triggered from ALK to ARS Pharma was $5.0 million, with $2.6 million recognized as revenue and the remaining $2.4 million recorded to the financing liability on the company’s balance sheet.

MORE ON ARS PHARMACEUTICALS

* ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine [https://seekingalpha.com/article/4800366-ars-pharmaceuticals-high-risk-high-reward-rollout-of-no-needle-epinephrine]
* ARS Pharmaceuticals: 'Betting On The Come' [https://seekingalpha.com/article/4800201-ars-pharmaceuticals-betting-on-the-come]
* Seeking Alpha’s Quant Rating on ARS Pharmaceuticals [https://seekingalpha.com/symbol/SPRY/ratings/quant-ratings]
* Historical earnings data for ARS Pharmaceuticals [https://seekingalpha.com/symbol/SPRY/earnings]
* Financial information for ARS Pharmaceuticals [https://seekingalpha.com/symbol/SPRY/income-statement]